PD-0332991 (palbociclib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PD-0332991 (palbociclib), covering 2021-01-20 to 2021-01-20. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib [Phase 2]